Afternoon trading July 10, page-150

As mentioned yesterday, BIT nearing the continuation of its breakout.



Biotron is presenting at the International AIDS Conference today with its Mode Of Action on how its lead drug, BIT225, clears HIV and re-enables the immune response. This MOA has been missing from their technology knowledge since when in October 2018 they released their initial HIV trial results, and when the share price spiked to 45c. Now that Biotron has a fuller understanding of the BIT225 effiacy, then it becomes a more attractive target for big pharma, and if it is going to occur, a partnership should develop in the near term. Furthermore, the COVID19 results are still pending, and the 5 month silence is more likely signifying more chance of success than not. The technology that has brough them this far on HIV is as equally applicable to C19. I suggest that the health of the chart and the stack is representing this.